Neumora Therapeutics, Inc. (NMRA) Live Share Price, Invest From India

Neumora Therapeutics, Inc. Stock Performance

as on May 15, 2026 at 2:15 pm IST

Day's Low
Day's High
$1.76
Day's Price Range
$1.99
$1.97
10.66%
Downside
1.02%
Upside
52 Week's Low
52 Week's High
$0.62
52-Week Price Range
$3.65
$1.97
68.73%
Downside
85.28%
Upside

Neumora Therapeutics, Inc. share price movements today

Previous Close: $1.78
Open: $1.79
Volume: 1.9M
Day's Low - High: $1.76 - $1.99
52 Week Low - High: $0.62 - $3.65

Neumora Therapeutics, Inc. Historical Returns

1 Month Return: -4.37 %
3 Month Return: -38.44 %
1 Year Return: + 195.88 %
3 Year Return: 0 %
5 Year Return: 0 %

Neumora Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Neumora Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$329.8M

EPS (TTM)

-0.96

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-235.9M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-121.21%

Neumora Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Neumora Therapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Neumora Therapeutics, Inc.	BUY	$329.8M	NA	NA	0.00%
Alnylam Pharmaceuticals Inc	BUY	$38.9B	116.25%	73.05	12.55%
BeiGene, Ltd.	NA	$31.6B	NA	68.92	8.94%
Vertex Pharmaceuticals Inc	BUY	$115.0B	107.48%	26.89	35.51%
Regeneron Pharmaceuticals Inc	BUY	$75.5B	37.99%	17.58	29.65%

Stock Returns calculator for Neumora Therapeutics, Inc. Stock including INR - Dollar returns

The Neumora Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Neumora Therapeutics, Inc. investment value today

Current value as on today

₹3,29,694

Returns

₹2,29,694

(+229.69%)

Returns from Neumora Therapeutics, Inc. Stock

₹1,94,030 (+194.03%)

Dollar Impact

₹35,664 (+35.66%)

Analyst Recommendation on Neumora Therapeutics, Inc. Stock

Based on 12 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 12 analysts, 91.67% of analysts recommend a 'BUY' rating for Neumora Therapeutics, Inc.. Average target price of $8.91

Neumora Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Neumora Therapeutics, Inc..

What analysts predicted

77.89%UPSIDE

Target Price

$8.91

Current Price

$1.97

Analyzed by

12 Analysts

Target

$8.91

Neumora Therapeutics, Inc. target price $8.91, a slight upside of 77.89% compared to current price of $1.97. According to 12 analysts rating.

Indian Investors' Interest in Neumora Therapeutics, Inc. Stock

Search interest for Neumora Therapeutics, Inc. Stock has increased by 29% in the last 30 days, reflecting an upward trend in search activity.

Time period: April 15, 2026 to May 15, 2026

Change:29% versus previous 30 day period

Neumora Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Total Revenue	-	-	-	-	-	-	-	-	-
Gross Profit	0	0	0	-	-	-	-	-5	-
Operating Income	-50	-60	-63	-76	-62	-70	-54	-57	-58
EBITDA	-108	-59	-63	-76	-62	-70	-54	-55	-57
Interest Expense	-	-	-	-	-	-	-	0	2
Depreciation	0	0	0	0	0	0	0	0	0
Income Before Tax	-108	-53	-58	-72	-58	-67	-52	-56	-59
Income Tax Expense	0	-6	0	0	-	0	0	-	-
Net Income	-108	-53	-58	-72	-58	-67	-52	-56	-59
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Neumora Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-
Gross Profit	-	-1	-2	0	-	-5
Operating Income	-95	-237	-135	-188	-263	-241
EBITDA	-95	-236	-135	-187	-262	-233
Interest Expense	-	-	-	-	-	3
Depreciation	0	0	0	0	0	0
Income Before Tax	-99	-237	-130	-235	-243	-236
Income Tax Expense	0	0	-4	0	0	0
Net Income	-99	-237	-130	-235	-243	-236
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Neumora Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-53	-58	-72	-58	-67	-52	-56	-59	-53
Operating Cash Flow	-42	-56	-33	-50	-59	-52	-46	-47	-46
Investing Cash Flow	-150	21	156	-98	44	30	51	42	0
Financing Cash Flow	1	2	1	15	-	18	0	58	10
Change in Cash	-191	-32	125	-133	-15	-3	4	53	-35

Neumora Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-99	-237	-130	-235	-243	-236
Operating Cash Flow	-26	-75	-114	-163	-182	-206
Investing Cash Flow	-11	0	-168	64	-70	168
Financing Cash Flow	230	293	115	231	21	77
Change in Cash	192	217	-167	133	-231	39

Insights on Neumora Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, NMRA has outperformed top 5 stocks with highest market-cap in its industry
NEGATIVE IMPACT
Price Dip
In the last 3 months, NMRA stock has moved down by -44.4%

About Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Organisation	Neumora Therapeutics, Inc.
Headquarters	260 Arsenal Place, Watertown, MA, United States, 02472
Industry	Biotechnology
CEO	Dr. Joshua Pinto Ph.D.
E-voting on shares	Click here to vote

Key Management of Neumora Therapeutics, Inc.

Name	Title
Helen Rubinstein	Head of Investor Relations
Ms. Amy Sullivan	Chief Human Resources Officer
Dr. Joshua Pinto Ph.D.	President
Ms. Carol Suh	Co-Founder & Chief Strategy Officer
Dr. Nicholas Brandon Ph.D.	Chief Scientific Officer
Mr. Jason G. Duncan J.D.	Chief Legal & Administrative Officer
Ms. Lori Houle	Chief Technical Operations & Quality Officer
Dr. Daljit Singh Aurora Pharm.D.	Chief Operationg & Development officer
Mr. Michael Lee Milligan	CFO & Principal Accounting Officer
Mr. Pablo Gersberg	Chief Information Officer

FAQs

What is Neumora Therapeutics, Inc. share price today?

Neumora Therapeutics, Inc. share price today is $1.97 as on May 15, 2026 at 8:45 am IST at the close of the market. Neumora Therapeutics, Inc. share today touched a day high of $1.99 and a low of $1.76.

What is the 52 week high and 52 week low for Neumora Therapeutics, Inc. share?

Neumora Therapeutics, Inc. share touched a 52 week high of $3.65 on February 18, 2026 and a 52 week low of $0.62 on May 15, 2025. Neumora Therapeutics, Inc. stock price today i.e. May 15, 2026 at 8:45 am IST is closed at $1.97,which is 46.03% down from its 52 week high and 219.75% up from its 52 week low.

What is Neumora Therapeutics, Inc.'s market capitalisation today?

Neumora Therapeutics, Inc. market capitalisation is $0.00T as on May 15, 2026 at 8:45 am IST.

How to invest in Neumora Therapeutics, Inc. Stock (NMRA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Neumora Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Neumora Therapeutics, Inc. Shares that will get you 0.7614 shares as per Neumora Therapeutics, Inc. share price of $1.97 per share as on May 15, 2026 at 8:45 am IST.

What is the minimum amount required to buy Neumora Therapeutics, Inc. Stock (NMRA) from India?

Indian investors can start investing in Neumora Therapeutics, Inc. (NMRA) shares with as little as ₹95.753 or $1 (as of May 15, 2026 at 2:42 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹957.53 in Neumora Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on May 15, 2026 at 2:42 pm IST). Based on Neumora Therapeutics, Inc. share’s latest price of $1.97 as on May 15, 2026 at 8:45 am IST, you will get 5.0761 shares of Neumora Therapeutics, Inc.. Learn more about fractional shares .